Newsroom

Our central location for research news and other stories of related information can be found here.

Wednesday, February 13, 2013

Coronoary Arteries Healed with Dissolvable Stents - Radio Interview

The 4 billion dollar coronary stent market is about to get bigger. Bioresorbable stents are performing well, giving patients and doctors more options. Cincinnati's Christ Hospital is the lead hospital in a national study. Ann Thompson reports how Absorb™ works and what it could mean for the market.

Click Here to Listen to the Interview with Dr. Dean Kereiakes

Tuesday, December 11, 2012

First Synergy stents implanted in EVOLVE II trial

The first procedures to implant the novel Synergy bioabsorbable polymer drug-eluting stent as part of the EVOLVE II trial were recently performed at The Christ Hospital in Cincinnati. The procedures were performed by Thomas Broderick, MD, and Joseph Choo, MD, interventional cardiologists at the hospital.

Read The Full Article. (Click Here)

Monday, December 3, 2012

THE CHRIST HOSPITAL ON CUTTING EDGE OF NEW STENT TECHNOLOGY; IMPLANTS INVESTIGATIONAL NEW DEVICE

CINCINNATI, Ohio – December 3, 2012 – Clinical scientists at The Christ Hospital’s Lindner Research Center are leading a worldwide study evaluating new breakthrough coronary stent technology that may make stenting easier and safer.

Read The Full Article. (Click Here)

Monday, September 24, 2012

Dr Sarembock on trans-catheter aortic valve replacement (TAVR)

Nearly one in every eight Americans aged 75 and older will be diagnosed with valvular heart disease. Open-heart surgery has traditionally been the standard approach to treating this increasingly prevalent disease. But many elderly patients cannot undergo the rigors of conventional surgery, creating an urgent need for less invasive, non-surgical solutions for valve disease patients. On 10th September, Dr Sarembock gave our team some of his precious time in explaining the TAVR procedure.

Read The Full Article. (Click Here)

Monday, April 16, 2012

ACC: Novel therapy lowers LDL-C by 72%

A novel monoclonal antibody lowered low density lipoprotein cholesterol (LDL-C) up to 72 percent in patients with primary hypercholesterolemia in a randomized, double-blind, placebo-controlled trial. The results were announced March 26 at the American College of Cardiology’s 61st scientific session and simultaneously published online in the Journal of the American College of Cardiology.

“This was a very sophisticated trial that gleaned a lot of information,” said co-author Dean J. Kereiakes, MD, medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, in an interview. The study was designed to test the safety and efficacy of the human monoclonal antibody SAR236553/REGN727.

Read the Full Article. (Click Here)

Watch the Video. (Click Here)

After an Unprecedented Request for a Retraction, A Close Look at the Data

Guest Post from Edward J. Schloss, MD, the medical director of cardiac electrophysiology at Christ Hospital in Cincinnati, OH.

Last week, St. Jude Medical took the unusual step of requesting a retraction of an article accepted for publication in Heart Rhythm Journal. In this article Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads, Dr. Robert Hauser et al analyzed patient deaths in the FDA MAUDE database associated with St. Jude Medical and Medtronic ICD leads. This week, Dr. Douglas Zipes, Heart Rhythm editor, declined that request. (Please see my previous Cardiobrief coverage of Hauser’s article.)

Read the Full Article. (Click Here)